Skip to content

Author

Paulina N. Esguerra

We have 3 of 6 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract A036: Elucidating MYC allelic imbalance and therapeutic response in pancreatic ductal adenocarcinoma via patient-derived organoids

Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with an unmet need for novel precision based therapies. While KRAS canonically drives tumor progression, MYC amplification has emerged as a critical downstream resistance mechanism. Efforts have been made to elucidate the role of MYC amplification in PDAC...

Audrey G. Sawyer, Lauryn E. Flannagan, Paulina N. Esguerra et al. · 0 citations
Sep 2026

Abstract B127: Synthetic Lethality Through Combined BET and CDK9 Inhibition in MYC-Amplified Pancreatic Ductal Adenocarcinoma

It is demonstrated that dual BET and CDK9 inhibition promotes transcriptional pausing and suppresses key regulators in transcriptionally driven cancers, as well as demonstrating on-target transcriptional inhibition.

Paulina N. Esguerra, Michela Cadarso, Sasha Livingwell et al. · 0 citations
Sep 2026

Abstract B043: Targeting dual CDK9 and KRASG12D selective inhibition as a novel combination therapy in pancreatic ductal adenocarcinoma

A patient-derived cancer organoid (PCO) model that is MYC-amplified is examined to assess the activity of combining CDK9 inhibition (SLS009) with tricomplex RAS (ON inhibitors) studying both RMC-6236 and RMC-9805 and significantly augments the induction of apoptosis and necrosis compared to single agent activity.

Michela Cadarso, Paulina N. Esguerra, Lauryn E. Flannagan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.